In fi­nal re­port, ICER ap­pears to have a change of heart on new acute mi­graine ther­a­pies

ICER ap­pears to have re­versed course on its as­sess­ment of two acute mi­graine ther­a­pies.

The cost-ef­fec­tive­ness watch­dog in No­vem­ber is­sued a draft re­port sug­gest­ing that ex­ist­ing gener­ic med­i­cines are more ef­fec­tive and cheap­er than Al­ler­gan’s De­cem­ber-ap­proved CGRP ubro­gepant, Bio­haven ri­val mol­e­cule, rimegepant (which is un­der FDA re­view), and Lil­ly’s Oc­to­ber-sanc­tioned las­mid­i­tan, which binds to 5-HT1F re­cep­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER